Chemoprevention of the breast cancer;Quimioprevención del cáncer de mama

Revisiones en Cancer

Volumn 16, Issue 4, 2002, Pages 138-153

  Pico Navarro C ^a   Bosch Jose F X ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CARCINOMA; CHEMOPROPHYLAXIS; HUMAN; REVIEW;

EID: 0036376087     PISSN: 02138573     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Quimioprevención delcáncer de mama
2. Cancer prevention by delay
3. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
4. Tamoxifen prevention of breast cancer: An instance of the fingerpost
5. American Society of Clinical Oncology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and raloxifen
6. Estimación de la incidencia de cáncer en Espafia: Periodo 1993-1996
7. Variations in survival from breast cancer in Europe by age and country, 1978-1989
8. Malignant tumors of the breast
9. Is screening for breast cancer with mammography justifiable?
10. Cochrane review on screening for breast cancer with mammography
11. All-cause mortality in randomized trials of cancer screening
12. Mammographic screening: No reliable supporting evidence?
13. Hereditary cancer - The evidence for current recommended management
14. Practical guide for estimating risk for familial breast cancer
15. Risk of familial breast cancer
16. Family history and risk of breast cancer
17. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
18. Graphs to estimate an individualized risk of breast cancer
19. Autosomal dominant inheritance of early-onset breast cancer
20. Validation of a breast cancer risk assessment model in women with a positive family history
21. Validation of the Gail, et al. Model for predicting individual breast cancer risk
22. Validation studies for models projecting the risk of invasive and total breast cancer incidence
23. Validation of the Gail et al. Model of breast cancer risk prediction and implications for chemoprevention
24. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
25. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
26. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2
27. Assessing the risk of breast cancer
28. Understanding mathematical models for breast cancer risk assessment and counseling
29. Validating and improving models for projecting the absolute risk of breast cancer
30. Estrogen and the risk of breast cancer
31. Bone mass and the risk of breast cancer among postmenopausal women
32. Bone mass and breast-cancer risk in older women: Differences by stage at diagnosis
33. 17b-estradiol is carcinogenic in human breast epithelial cells
34. Do strogens always increase breast cancer risk?
35. Production and actions of estrogens
36. Molecular determinants for the tissue specificity of SERMs
37. Oestrogen/insulin-like growth factor-I resceptor interaction in early breast cancer: Clinical implications
38. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer
39. The role of mitogen-activated protein (MAP) kinase in breast cancer
40. Expression profile of tyrosine kinases in breast cancer
41. Field cancerizaction, clonality, and epithelial stem cells: The spread of mutated clones in epithelial sheets
42. Characterization of bipotent mammary epithelial progenitor cells in normal adult breast tissue
43. Molecular portraits of human breast tumours
44. Gene-expression profiles in hereditary breast cancer
45. A SAGE (Serial Analisis of Gene Expresión) view of breast tumor progresion
46. Molecular changes in normal breast epithelial cells and "borderline" epithelial proliferations-implications for classification of breast disease
47. Gene expresión profiling predicts clinical outcome of breast cancer
48. Identification of molecular targets associated with selium-induced growth inhibition in human breast cells using cDNA microarrays
49. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development
50. The hallmarks of cancer
51. Tumors are unique organs defined by abnormal signaling and context
52. Stromal cells can contribute oncogenic signals
53. Angiogenesis and inflammation in ductal carcinoma in situ of the breast
54. Distinct angiogenic patters are associated with high-grade in situ ductal carcinomas of the breast
55. Vascular permeability factor (Vascular Endothelial Growth Factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
56. Angiogenesis and expression of thymidine phosphorilase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast
57. Pathobiologic findings in DCIS of the breast: Morphologic features, angiogenesis, HER-2/neu and hormone receptors
58. Aromatase regulation and breast cancer
59. Local endocrine effects of aromatase inhibitors within the breast
60. Modulation of aromatase expression in human breast tissue
61. Prostaglandins and breast cancer
62. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors
63. Cyclooxigenase-2 expression in human breast cancer and ductal carcinoma in situ
64. Correlation of aromatase and cyclooxigenase gene expression in human breast cancer specimens
65. Aromatase and COX-2 expression in human breast cancers
66. Nitric oxide, prostanoids, cyclooxigenase, and angiogenesis in colon and breast cancer
67. Cyclooxigenase-2 inhibition by Celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo
68. MRNA expresion of cyco-oxigenase-2 (cox-2) and vascular endotelial growth factor (VEGF) in human breast cancer
69. Prognostic significance of elevated ciclo-oxigenase-2 expression in breast cancer
70. Molecular pathology of cyclooxygenase-2 in neoplasia
71. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells
72. Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis
73. Phase III, large-scale chemoprevention trials
74. Models for early chemoprevention trials in breast cancer
75. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model
76. Beyond tamoxifen. New endpoints for breast cancer chemoprevention, new drugs for breast cancer
77. Biomarker assays in nipple aspirate fluid
78. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid
79. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer
80. Breast patterns as an index of risk for developing breast cancer
81. Mammographic features and breast cancer risk: Effects with time, age, and menopause status
82. Plasma Insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density
83. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian national breast screening study
84. Effect of tamoxifen on mammographic density
85. Digitized mammography: A clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo
86. Measurement of breast density with dual x-ray absortiometry: Feasibility
87. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
88. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study
89. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors
90. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women
91. Outcomes of tamoxifen chemoprevention for breast cancer in very hight-risk women: A cost-effectiveness analysis
92. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial
93. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial
94. Prevention of breast cancer with tamoxifen: Preliminary findings from the italian randomized trial among hysterectomised women
95. Tamoxifen for breast cancer among Hysterectomised women
96. Update of new studies in Europe
97. A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials
98. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial
99. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial
100. Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants
101. Serum estradiol level and risk of breast cancer during treatment with raloxifene
102. Cognitive function in post-menopausal women treated with raloxifene
103. Raloxifene and cardiovascular events in osteoporotic postmenopausal women
104. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer
105. Patient reluctance toward tamoxifen use for breast cancer primary prevention
106. Women's interest in chemoprevention for breast cancer
107. Chemoprevention with aromatase inhibitors: Trial strategies
108. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women
109. Postmenopausal hormone-replacement therapy
110. The effects of exemestane on bone and lipids in the ovariectomized rat
111. Retinoids and their receptors in cancer development and chemoprevention
112. Randomized trial of fenretidine to prevent second breast malignancy in women with early breast cancer
113. Chemoprevention of breast cancer with fenretidine
114. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenil)Retinamide in combination with tamoxifen in patiens at high risk for developing breast cancer
115. Fenretidine vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen, an Eastern Cooperative Oncology Group phase III Intergroup Trial (EB193, INT-0151)
116. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations
117. Breast cancer and NSAID use: A metaanalysis
118. Chemoprevention of breast cancer in rats by Celecoxib, a cyclooxygense-2 inhibitor
119. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer
120. Cyclooxygenase-2: A pharmacologic target for the prevention of cancer
121. Chemoprevention of cancer
122. Cancer chemoprevention
123. Hobson's choice and the need for combination of new agents for the prevention and treatment of breast cancer
124. Effect of exemestane and celecoxib alon or in combination on DMBA-induced mammary carcinoma in rats